Free tool
FAERS Monitor: Rinvoq Lq
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218347 or its brand name (Rinvoq Lq, Upadacitinib). Reports on generic versions are filed under their own applications.
Reports
85,284
Serious
58,460
69% of reports
Hospitalization
21,428
Death reported
3,196
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pain5,607
- arthralgia5,049
- drug ineffective4,961
- rheumatoid arthritis3,494
- covid-193,238
- pain in extremity2,951
- fatigue2,855
- surgery2,719
- fall2,624
- headache2,052
- pneumonia2,046
- death2,040
- therapy interrupted1,894
- diarrhoea1,889
- back pain1,833
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 5 |
| 2018 | 7 |
| 2019 | 221 |
| 2020 | 2,841 |
| 2021 | 5,924 |
| 2022 | 16,500 |
| 2023 | 15,076 |
| 2024 | 15,234 |
| 2025 | 17,249 |
| 2026 | 12,226 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,968,875 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| surgerySignal | 2,719 | 11.9 | 11.5 | 26,065 |
| rheumatoid arthritisSignal | 3,494 | 7.8 | 7.5 | 20,175 |
| therapy interruptedSignal | 1,894 | 6.7 | 6.4 | 8,942 |
| covid-19Signal | 3,238 | 4.6 | 4.5 | 9,082 |
| arthralgiaSignal | 5,049 | 3.0 | 2.9 | 6,870 |
| pain in extremitySignal | 2,951 | 2.5 | 2.4 | 2,628 |
| painSignal | 5,607 | 2.3 | 2.2 | 4,031 |
| back pain | 1,833 | 2.0 | 1.9 | 855 |
| fall | 2,624 | 2.0 | 1.9 | 1,227 |
| pneumonia | 2,046 | 1.6 | 1.5 | 417 |
| drug ineffective | 4,961 | 0.9 | 0.9 | 29 |
| fatigue | 2,855 | 0.9 | 0.9 | 30 |
| headache | 2,052 | 0.8 | 0.8 | 98 |
| diarrhoea | 1,889 | 0.7 | 0.7 | 210 |
| death | 2,040 | 0.6 | 0.6 | 633 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.